Drug Profile
Bucillamine - AYUMI Pharma
Alternative Names: Rimachil; RimatilLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Santen Pharmaceutical
- Developer AYUMI Pharma
- Class Antigouts; Antivirals; Cysteines; Disease-modifying antirheumatics; Nonsteroidal anti-inflammatories; Small molecules; Sulfhydryl compounds; Sulfur amino acids
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Rheumatoid arthritis
- Discontinued Osteoarthritis
Most Recent Events
- 29 May 2018 Discontinued - Preclinical for Osteoarthritis in Japan (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Osteoarthritis in Japan (PO, Tablet)
- 18 Jul 2007 Preclinical trials in Osteoarthritis in Japan (PO)